Treatment of the patient with diabetes: Importance of maintaining target HbA1c levels

Current Medical Research and Opinion

Volumn 20, Issue 12, 2004, Pages 1919-1927

  Davidson, Jaime A ^a  

^a Dallas Diabetes and Endocrine Center   (United States)

Author keywords

Diabetes mellitus; Diabetic complications; HbA1c; Insulin; Intensive glycemic control; Oral hypoglycemic agents

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; HUMULIN L; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ANOREXIA; BACKACHE; BLOATING; CLINICAL TRIAL; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DISEASE COURSE; FATIGUE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LACTIC ACIDOSIS; LIVER TOXICITY; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; MORTALITY; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; VOMITING; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PROGNOSIS;

EID: 13144307081     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X6291     Document Type: Review

References (49)

1. Center for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates on diabetes. Available from http://www.cdc.gov/diabetes/pubs/ estimates.htm. [Accessed 17 March 2004]
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
3. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
4. Camacho P, Pitale S, Abraira C. Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus. Drugs Aging 2000;17:463-76
5. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-32
6. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 summary. Adv Data 2002:1-32
7. Abel M, Krokowski M. Pathophysiology of immune-mediated (type 1) diabetes mellitus: potential for immunotherapy. BioDrugs 2001;15:291-301
8. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 2000;(Suppl 113):3-13
9. American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care 2004;27(Suppl 1):s1-s150
10. American College of Endocrinology, American Association of Clinical Endocrinologists. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 2002;8(Suppl 1):5-11
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977-86
12. American Diabetes Association. Management. In: Kelley DB, et al., editors. Medical management of type 2 diabetes, 4th ed. Alexandria (VA): American Diabetes Association; 1998. p. 34-86
13. Noble SL, Johnston E, Walton B. Insulin lispro: a fast-acting insulin analog. Am Fam Physician 1998;57:279-92
14. Hirsch IB. Intensive treatment of type 1 diabetes. Med Clin North Am 1998;82:689-719
15. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH; the Benelux-UK Insulin Lispro Study Group. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 1997;20:1827-32
16. Home PD, Lindholm A, Hylleberg B, Round P for the UK Insulin Aspart Study Group. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 1998;21:1904-9
17. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67
18. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
19. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA for the US Study Group of Insulin Glargine in Type 1 Diabetes. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-43
20. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8
21. UKPDS Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism 1990;39:905-12
22. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303
23. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992;15:755-72
24. Bischoff H. Pharmacology of α-glucosidase inhibition. Eur J Clin Invest 1994;24(Suppl 3):3-10
25. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26:511-22
26. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res 1995;27:263-6
27. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355:1008-10
28. Dunn CJ, Faulds D. Nateglinide. Drugs 2000;60:607-15
29. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of endocrine pancreas. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw Hill; 2001. p. 1679-714
30. Rossetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Clin Invest Med 1995;18:255-60
31. Prescribing information: Avandia®. Physicians' Desk Reference®, 57th ed. Montvale (NJ): Medical Economics Company, Inc.; 2003. p. 1473-7
32. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-5
33. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC for the UK Prospective Diabetes Study (UKPDS) Group. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998;15:297-303
34. Ovalle F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract 1998;4:146-7
35. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
36. Riddle MC, Rosenstock J, for the HOE 901/4002 Study Group. Treatment to target study: insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes. Successful control with less nocturnal hypoglycemia [abstract 457-P]. Diabetes 2002;51(Suppl 2):A113
37. Rosenstock J, Riddle MC, for the HOE 901/4002 Study Group. Treatment to target study: timing and frequency of nocturnal hypoglycemia. The value of adding bedtime basal insulin glargine over NPH insulin in insulin-naive patients with type 2 diabetes on oral agents [abstract 1982-PO]. Diabetes 2002;51(Suppl 2):A482
38. Riddle M, Hart J, Bingham P, Garrison C, McDaniel P. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci 1992;303:151-6
39. Yki-Järvinen H, Dressler A, Ziemen M for the HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-6
40. 1c. Diabetes Care 2000;23:1236-41
41. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997;20:1539-42
42. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996;124:90-6
43. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7
44. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68
45. Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-98
46. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903
47. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
48. Hollander PA. Current trends in treating type 2 diabetes. Postgrad Med 2000;Special Report:4-10
49. 1c is our best outcome measure: let's use it. Clinical Diabetes 1996:79-82